We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Potential Biomarker Determines Risk of Type 2 Diabetes

By LabMedica International staff writers
Posted on 08 Oct 2013
A definitive link has been discovered between certain lifestyle and demographic factors and a potential biomarker to determine the risk of type 2 diabetes.

The biomarker is a protein called sex hormone binding globulin (SHBG) and low levels can be an indication of increased risk for metabolic syndrome and type 2 diabetes years in advance.

Scientists at Brown University (Providence, RI, USA) measured the levels of SHBG in 13,547 women who were a part of the national Women's Health Initiative. More...
Although the team had found that SHBG levels are able to predict the risk of type 2 diabetes, and that several mutations in the genetic coding for the protein are also predictive factors, they say this study shows protein does not necessarily remain unchanged throughout the lifetime of the individual.

Plasma SHBG concentrations were measured using an electrochemiluminescence immunoassay (Roche Diagnostics; Indianapolis, IN, USA), a solid-phase two-site chemiluminescent immunoassay (Siemens Healthcare Diagnostics; Malvern, PA, USA), or an immunoradiometric assay (Esoterix Laboratory Services; Austin, TX, USA).

In the analysis of the results, the scientists found that age, use of estrogen replacement therapy, physical activity, and coffee consumption were significantly higher in women with higher SHBG levels. However, women with a high body mass index (BMI) were linked to low SHBG levels, but the significant associations of SHBG in women did not vary between ethnic groups. The results of the study could also lead to potential new interventions, as BMI, physical activity, estrogen therapy and coffee intake can all be adjusted. The authors noted that by knowing these factors are linked to the biomarker, this suggests changing these elements of lifestyle could, in turn, adjust levels of protein over time, therefore affecting the risk of diabetes.

Simin Liu, MD, ScD, a professor of medicine at Brown, and the senior author of the study said, “This protein seems to capture the cumulative effect between the gene and our environment in reflecting a metabolic state of our body, particularly in the liver, ultimately affecting diabetes risk. By the time you are checking blood glucose it's too late, because you use that as a diagnostic criterion to define diabetes. Our argument is that you can go to the doctor's office and check this protein that can predict your future risk 6 to 10 years down the line." The study was published on September 18, 2013, in the journal Clinical Chemistry.

Related Links:

Brown University
Roche Diagnostics
Siemens Healthcare Diagnostics




Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.